Clinical and translational studies in NSCLC have shown that STING pathway activation of peripheral blood immune cells (PBMCs) correlates with the expression of immune-related genes, CD8+ T-cell infiltration as well as response to immunotherapy (55). This evidence concerns the gene CD8A and non-small cell lung carcinoma.